Received Aug 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | LM99N | — |
9-year-old female patient received an adult dose of Havrix; 9-year-old female patient received an adult dose of Havrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of overdose in a 9-year-old female patient who received HAV (Havrix adult) (batch number LM99N, expiry date 01-MAR-2026) for prophylaxis. On 04-AUG-2025, the patient received the 1st dose of Havrix adult. On 04-AUG-2025, an unknown time after receiving Havrix adult, the patient experienced overdose (Verbatim: 9-year-old female patient received an adult dose of Havrix) and adult product administered to child (Verbatim: 9-year-old female patient received an adult dose of Havrix). The outcome of the overdose and adult product administered to child were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 18-AUG-2025 The medical assistant reported that a 9-year-old patient received an adult dose of Havrix vaccine, which led to an adult product administered to child and overdose. She called to know how to proceed after this incident. The vaccine administration facility was the same as primary reporter.